CTLA-4 inhibitors enhance the anti-tumor effects of IL-36 by inhibiting Tregs, resulting in increased proliferation of CD8+ T cells and IFN-γ production, which act synergistically with cisplatin [176]. The gene discussed is IFNG; the disease is neoplasm.